4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development. Oncothyreon Inc. (USA) (NASDAQ:ONTY) stock performance was 1.92% in last session and finished the day at $3.72. Traded volume was 1.16 million shares in the last…
Biopharmaceutical giant Oxigene Inc (NASDAQ:OXGN) y reported its experimental drug Zybrestat, combined with Roche’s cancer drug Avastin, significantly slowed progression of recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN) stock performance was 77.27% in last session and finished the day at $4.29. Traded volume was 29,290,814 million shares in the last session and the average volume of…
Marina Biotech, Inc. (OTCMKTS:MRNA) illustrated a similar run of events, as it reinvigorated its PR activity in the new year and shot upwards as it received a patent protection for one of its therapies. MRNA is back at $1.38, after it slumped for a while following a temporary peak at $1.70. Marina Biotech, Inc. (OTCMKTS:MRNA)…
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for…
Northwest Biotherapeutics Inc (NASDAQ:NWBO) a biotechnology company developing DCVax personalized immune therapies for solid tumour cancers, has received approval from the Paul Ehrlich Institute (PEI- the FDA of Germany) of a “Hospital Exemption” early access programme under Section 4b of the German Drug Law. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 16.93% in last session…
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was a big mover last session, as its shares rose nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the healthcare company since Feb 24, as the stock is now down nearly…
